Fidelis Capital Partners, LLC Kezar Life Sciences, Inc. Transaction History
Fidelis Capital Partners, LLC
- $654 Billion
- Q1 2024
A detailed history of Fidelis Capital Partners, LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Fidelis Capital Partners, LLC holds 27,266 shares of KZR stock, worth $17,177. This represents 0.03% of its overall portfolio holdings.
Number of Shares
27,266Holding current value
$17,177% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding KZR
# of Institutions
84Shares Held
44.9MCall Options Held
2.6KPut Options Held
600-
Suvretta Capital Management, LLC New York, NY7.17MShares$4.52 Million0.28% of portfolio
-
Avidity Partners Management LP Dallas, TX5.03MShares$3.17 Million0.17% of portfolio
-
Black Rock Inc. New York, NY4.62MShares$2.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$1.95 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L32.05MShares$1.29 Million0.29% of portfolio
About Kezar Life Sciences, Inc.
- Ticker KZR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,369,504
- Market Cap $43.1M
- Description
- Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...